iGlarLixi effectively reduces residual hyperglycemia in patients with type 2 diabetes on basal insulin: a post hoc analysis from the LixiLan-L study.

AIMS: Globally, nearly half of the patients with type 2 diabetes (T2DM) do not successfully achieve target HbA1c with basal insulin, despite meeting fasting plasma glucose (FPG) targets. In this post hoc analysis of the LixiLan-L study, we determined whether iGlarLixi, a fixed-ratio combination of insulin glargine Gla-100 (iGlar) and the glucagon-like peptide-1 receptor agonist lixisenatide (Lixi), addresses the challenge of reducing residual hyperglycemia in patients with T2DM. MATERIALS AND METHODS: In LixiLan-L, a randomized, open-label study (NCT02058160), 1018 patients with T2DM on basal insulin for ≥6 months ± oral antidiabetes drugs entered a 6-week run-in period, during which they were switched to and/or optimized for a daily dose of iGlar while continuing only metformin. Post run-in period, 736 patients were then randomized to receive iGlarLixi or were continued on iGlar for 30 weeks ± metformin. Residual hyperglycemia was defined as HbA1c ≥ 7.0% despite an FPG <140 mg/dL. RESULTS: The proportion of patients with residual hyperglycemia was similar in both treatment arms at screening (~42%), and increased post run-in period (~62%). After 30 weeks, the proportion of patients with residual hyperglycemia declined to 23.8% in the iGlarLixi vs. 47.1% in the iGlar arm (p < 0.0001). The proportion of patients achieving both HbA1c (<7.0%) and FPG (<140 mg/dL) targets was higher in the iGlarLixi compared with the iGlar arm (50.3% vs. 27.4%, respectively, p < 0.0001). CONCLUSION: iGlarLixi effectively reduces residual hyperglycemia in patients with T2DM on basal insulin therapy. This article is protected by copyright. All rights reserved.